相关实验视频

Updated: Jul 27, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

与高风险局部前列腺癌中新辅助化学激素治疗的差异性病理反应相关的预测因素

Junjie Fan¹, Hua Liang², Yanan Gu³

¹Department of Urology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P.R. China; Department of Urology, Baoji Central Hospital, Baoji, P.R. China.

Urologic oncology

|June 9, 2023

概括

预测前列腺癌对新辅助化学激素治疗 (NCHT) 的反应,可以使用手术前的PSA水平和AR/Ki-67表达. 较低的PSA和特定的AR/Ki-67水平表明对NCHT有良好的病理反应.

科学领域:

在瘤学瘤学.
泌尿器科泌尿器科泌尿器科泌尿器科
病理学病理学病理学

背景情况:

新辅助化学激素治疗 (NCHT) 是高风险局部性前列腺癌 (CaP) 的标准治疗方法.
预测对NCHT的病理反应对于定制治疗策略至关重要.
确定可靠的临床和分子预测因子仍然是一个未得到满足的需求.

研究的目的:

确定临床参数和分子生物标志物,预测前列腺癌中对NCHT的差异性病理反应.
评估这些生物标志物的预测准确性.

主要方法:

分析了128名高风险局部CaP接受NCHT和激进前列腺切除术 (RP) 的患者.
免疫组织化学被用来评估雄激素受体 (AR),AR拼接变体-7 (AR-V7) 和生物检查样本中的Ki-67.
病理反应是根据NCHT后的瘤体积和细胞减少等级的.

主要成果:

75.78%的患者对NCHT表现出良好的反应 (2-4级).
较低的手术前PSA,较低的AR表达和高的Ki-67表达预测了有利的反应.
基-67的ROC曲线下的面积 (AUC) 为0.723,表明其预测值.

结论:

下部手术前PSA是对NCHT有利的病理反应的独立预测因子.
活检样本中的AR和Ki-67表达水平与差异性反应有关.
低AR和高Ki-67表达的组合需要进一步调查,以预测有利的结果.

关键词:

这就是为什么AR AR AR AR.高风险的局部性前列腺癌在 Ki-67 机器人新辅助性化学激素疗法是一种新辅助性化学激素治疗.病理反应病理反应

更多相关视频

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...